FlashFeed

Full text

A recent audit of state Medicaid records revealed how pharmacy benefit managers are using complicated and sophisticated approaches for handling prescription drug claims that ultimately overcharge taxpayers, a finding that underscores controversy surrounding these crucial middlemen in the pharmaceutical supply chain.

The audit of Iowa’s state Medicaid program found that one large pharmacy benefit manager appeared to have made more than $100 million by adjusting the amount of money paid to pharmacies without passing some of the savings back to managed care plans working on behalf of the state, according to Iowa officials. The review scrutinized records from 2019 through 2021.

The overall conclusion was similar to audit results conducted in a few other states, but in this instance, the auditors identified what amounted to creative accounting maneuvers, which not only made it possible to obscure the flow of money but evade prohibitions on a controversial pricing practice that is now outlawed in Iowa and some other states.

Continue to STAT+ to read the full story…

Full text

Credit: X.com/MANGMI_Official

TL;DR

Upstart brand MANGMI has revealed chipset info for its upcoming Air Y series of Android handhelds.

The standard Air Y is equipped with the Snapdragon 662 chip, while the Air Y Pro has the Snapdragon 865.

This means the former device should handle everything up to PSP emulation, while the latter should handle PS2 and GameCube games.

Upstart brand MANGMI has been teasing two Game Boy-style Android handhelds for a while now. The company has already shown off the designs for the so-called Air Y series, and we’ve now got processor info.

MANGMI confirmed on X that the Air Y will be powered by the Snapdragon 662 chipset. Meanwhile, the Air Y Pro will be equipped with the Snapdragon 865 processor.

Full text

Novo Nordisk, maker of Ozempic and Wegovy, lists the telehealth company LifeMD on its website as a provider that offers “legitimate medicine sourcing and patient support” for people seeking GLP-1 drugs. But some former employees describe LifeMD differently, as a company that has sought to maximize the volume of prescriptions it doles out at the expense of patient safety.

Former workers told STAT that providers were pressed to expedite their work to a pace that was not clinically responsible, with two of them saying providers at times were expected to review the cases of 25 people per hour based only on electronic forms the patients filled out — the equivalent of spending about two minutes on each case.

The company also discouraged providers from asking what they felt were medically relevant questions to patients, so that they don’t “delay care,” former employees said.

Continue to STAT+ to read the full story…